Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages

Author:

Corbett Kizzmekia S.1,Moin Syed M.1,Yassine Hadi M.2,Cagigi Alberto1,Kanekiyo Masaru1,Boyoglu-Barnum Seyhan1,Myers Sky I.1,Tsybovsky Yaroslav3,Wheatley Adam K.1ORCID,Schramm Chaim A.1,Gillespie Rebecca A.1,Shi Wei1,Wang Lingshu1,Zhang Yi1,Andrews Sarah F.1,Joyce M. Gordon1,Crank Michelle C.1,Douek Daniel C.1,McDermott Adrian B.1,Mascola John R.1,Graham Barney S.1ORCID,Boyington Jeffrey C.1

Affiliation:

1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

2. Qatar University Biomedical Research Center, Doha, Qatar

3. Electron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA

Abstract

Current influenza vaccines are primarily strain specific, requiring annual updates, and offer minimal protection against drifted seasonal or pandemic strains. The highly conserved stem region of hemagglutinin (HA) of group 2 influenza A virus subtypes is a promising target for vaccine elicitation of broad cross-group protection against divergent strains. We used structure-guided protein engineering employing multiple protein stabilization methods simultaneously to develop group 2 HA stem-based candidate influenza A virus immunogens displayed as trimers on self-assembling nanoparticles. Characterization of antigenicity, thermostability, and particle formation confirmed structural integrity. Group 2 HA stem antigen designs were identified that, when displayed on ferritin nanoparticles, activated B cells expressing inferred unmutated common ancestor (UCA) versions of human antibody lineages associated with cross-group-reactive, broadly neutralizing antibodies (bNAbs). Immunization of mice led to protection against a lethal homosubtypic influenza virus challenge. These candidate vaccines are now being manufactured for clinical evaluation.

Funder

HHS | National Institutes of Health

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Frederick National Laboratory for Cancer Research

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Reference76 articles.

1. Global Burden of Influenza as a Cause of Cardiopulmonary Morbidity and Mortality

2. Centers for Disease Control and Prevention. 2018. Seasonal influenza vaccine effectiveness 2005–2018. CDC Atlanta GA. https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm. Accessed 15 May 3018.

3. Influenza vaccine immunology

4. A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases

5. Is It Possible to Develop a “Universal” Influenza Virus Vaccine?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3